A multifaceted precision approach to high risk prostate cancer
This project aims to use a precision medicine approach for men with high risk prostate cancer at significant risk of cancer recurrence. We take samples of prostate cancer from men with high risk cancer at the time of surgery and use a combination of cutting edge technologies to analyse individual patient’s cancer.
We are using various culture technologies to grow the cancer in the laboratory for drug screening as well as DNA sequencing of tumors to assess if there are potential targets for drug therapies or clinical trials. If cancer recurrence does occur in the future this information could be critical to selection of appropriate and effective individualised treatments -“forewarned is forearmed”. If the initial pilot study demonstrates utility, a larger clinical trial where this information will be utilised for the future management of men at the time of cancer recurrence would be instituted.
Investigators
| A/Prof Elizabeth Williams | APCRC-Q, IHBI, QUT |
| Dr Ian Vela | APCRC-Q, IHBI, QUT, PAH |
| Prof Dietmar Hutmacher | APCRC-Q, IHBI, QUT |
| Dr Benjamin Shepherd | PAH |
| Dr Ken Miles | PAH |
| DProf Matt Brown | IHBI, QUT, PAH |
| Dr Nathalie Bock | APCRC-Q, IHBI, QUT |
| Dr Saeid Alinezhad | APCRC-Q, IHBI, QUT |
Duration
Funding
| PA Research Foundation | $300,000 |
